Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder

BACKGROUND: Fluvoxamine therapy is used for treatment of patients with depressive disorder, but it is often ineffective, and some patients suffer from dose-dependent undesirable side effects such as vertigo, headache, indigestion, xerostomia, increased anxiety, etc. CYP2D6 is involved in the biotran...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharmgenomics Pers Med
Autors principals: Zastrozhin, Mikhail Sergeevich, Grishina, Elena Anatolievna, Denisenko, Nataliya Petrovna, Skryabin, Valentin Yurievich, Markov, Dmitry Dmitrievich, Savchenko, Ludmila Mikhailovna, Bryun, Evgeny Alekseevich, Sychev, Dmitry Alekseevich
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6029588/
https://ncbi.nlm.nih.gov/pubmed/29988737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S160763
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars